| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



From the * Department of Urology, Case Western
Reserve University, University Hospitals of Cleveland, Cleveland VA Medical
Center, Cleveland, Ohio; and
Auxilium
Pharmaceuticals, Inc, Norristown, Pennsylvania.
| Correspondence to: Allen D. Seftel, Department of Urology, Case Western Reserve University, University Hospitals of Cleveland, Cleveland VA Medical Center, 11100 Euclid Ave, Cleveland, OH 44106-5046 (e-mail: ads6{at}po.cwru.edu). |
300 ng/dL, n = 406, mean age 58 years)
reporting one or more symptoms of low testosterone were randomized to T gel
(50 mg/d and 100 mg/d), T patch, or placebo. Twenty-fourhour
pharmacokinetic profiles for T were obtained. The 3 primary end points
evaluated at 30 and 90 days posttreatment included a significant change in the
frequency of intercourse and nighttime erections per 7-day week as well as a
change in sexual desire measured on a Likert-type scale and calculated as a
mean daily score. At day 30, a significant increase from baseline in sexual
desire was noted for those on 100 mg/d T gel compared with those on 50 mg/d T
gel, T patch, or placebo (1.2 vs 0.4, 0.7, and 0.4, respectively). A
significant increase from baseline in the frequency of nighttime erections was
also noted for those on 100 mg/d T gel compared with those on 50 mg/d T gel or
placebo (51% of subjects in the 100 mg/d T gel group had an increase in
frequency vs 30% for the 50 mg/d T gel group and 26% in the placebo group).
Finally, a significant increase from baseline in the frequency of intercourse
was evidenced for those on 100 mg/d T gel compared with those on T patch or
placebo (39% of subjects in the 100 mg/d T gel group had an increase in
frequency vs 21% for the T patch group and 24% in the placebo group). Similar
results were seen for 100 mg/d T gel at day 90 for sexual desire and nighttime
erections vs placebo. These data demonstrate a clear relationship between
restoring serum T concentrations and improvement in certain parameters of
sexual function. We propose that threshold T levels are needed in order to
significantly affect improvements in sexual functioning.
Key words: Randomized controlled trial, androgen, gel, hypogonadism, sexual dysfunction
This article has been cited by other articles:
![]() |
M. Wald, M. Miner, and A. D. Seftel State of the Art Reviews: Male Menopause: Fact or Fiction? American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 132 - 141. [Abstract] [PDF] |
||||
![]() |
T. G. Travison, J. E. Morley, A. B. Araujo, A. B. O'Donnell, and J. B. McKinlay The Relationship between Libido and Testosterone Levels in Aging Men J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2509 - 2513. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bhasin, G. R. Cunningham, F. J. Hayes, A. M. Matsumoto, P. J. Snyder, R. S. Swerdloff, and V. M. Montori Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 1995 - 2010. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |